QLi5 Therapeutics will become a Global Top Proteasome Inhibitor Specialty Biotech based upon
QLi5 Therapeutics is a Network of several well known Korean and German Biotech and Institutions
A leading clinical stage biotech in Korea
A leading translational research institute in Europe
World renowned basic research institute in Germany
Prof. Robert Huber Nobel laureate, emeritus director of the Max Planck Institute for Biochemistry
History & Testimonials
QLi5 Therapeutics was founded in January 2020 by Qurient Co. Ltd, (Korea – Majority Shareholder), Lead Discovery Center GmbH (LDC – Germany), Max-Planck-Gesellschaft (MPG – Germany) and Nobel laureate Robert Huber.
We believe the LDC’s innovative proteasome inhibitors hold exceptional potential, and we are excited to be part of QLi5 Therapeutics to jointly advance them towards preclinical and clinical testing. We very much appreciate the LDC as long-term partner and prime source of external innovation.
The proteasome is a real treasure chest, and the launch of Qli5 Therapeutics enables us to harness its potential for the treatment of many diseases. Our new generation of proteasome inhibitors is set to overcome key challenges that have so far hampered a broader application of the first generation of covalently acting proteasome inhibitors.
he foundation of Qli5 Therapeutics is the current peak of our trustful and long-term collaborations with Robert Huber and Qurient, our exceptionally strong and committed South Korean partner. This joint venture is wonderful step forward in our mutual relationship and it is a great opportunity to translate the potential of the proteasome complex into more tangible benefits for patients.
Having previously licensed assets to Qurient, we are delighted to now jointly start-up a venture with Qurient. QLi5 provides excellent prospects to enable a much needed next generation of proteasome inhibitors. Bringing the company on track together with Qurient has been a swift and smooth endeavour.